Ciprofloxacin in the Treatment of Acute Exacerbations of Chronic Bronchitis

  • B. I. Davies
  • F. P. V. Maesen
  • C. Baur
Part of the Current Topics in Infectious Diseases and Clinical Microbiology book series (CTIDCM, volume 1)


Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin. The patients were divided into four groups of 20 patients each and administered either 500 mg, 750 mg (two different batches of tablets) or 1000 mg twice daily for ten days. Most of the patients with Haemophilus influenzae and Branhamella catarrhalis infections were treated successfully but the results in patients with Streptococcus pneumoniae and Pseudomonas aeruginosa infections were less satisfactory. Although the ciprofloxacin MICs for the latter organisms were relatively low, mean serum and sputum concentrations measured on the first day of treatment did not exceed 2–3 mg/l and 1–2.3 mg/l respectively. The overall clinical results for all dosage regimes were only fair, mainly due to failure to eradicate Streptococcus pneumoniae and Pseudomonas aeruginosa. Adverse effects (nausea, stomach pain or hallucinations) were seen in eight patients, causing treatment to be discontinued in five. It is concluded that ciprofloxacin is only of limited use in the treatment of respiratory tract infections unless Streptococcus pneumoniae is absent.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauernfeind, A., Petermüller, C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. European Journal of Clinical Microbiology 1983, 2: 111–115.PubMedCrossRefGoogle Scholar
  2. 2.
    Fass, R. J. In vitro activity of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1983, 24: 568–574.PubMedCrossRefGoogle Scholar
  3. 3.
    Muytjens, H., van der Ros-van de Repe, J., van Veldhuizen, G. Comparative activities of ciprofloxacin (Bay 09867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrobial Agents and Chemotherapy 1983, 24: 302–304.PubMedCrossRefGoogle Scholar
  4. 4.
    Wise, R., Andrews, J. M., Edwards, L. J. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 23: 559–564.PubMedCrossRefGoogle Scholar
  5. 5.
    Davies, B. I., Maesen, F. P. V., Teengs, J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement C: 83–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Maesen, F. P. V., Davies, B. I., Teengs, J. P. Pefloxacin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1985, 16: 379–388.PubMedCrossRefGoogle Scholar
  7. 7.
    Medical Research Council Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965, i: 775–779.Google Scholar
  8. 8.
    Mulder, J., Goslings, W. R. O., van der Plas, M. C., Lopez Cardozo, P. Studies on the treatment with antibacterial drugs of acute and chronic bronchitis caused by Haemophilus influenzae. Acta Medica Scandinavica 1952, 143: 32–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Cowan, S. T., Steele, K. J. Identification of medical bacteria. Cambridge University Press, London, 1974.Google Scholar
  10. 10.
    Garrod, L. P., Lambert, H. P., O’Grady, F. Antibiotic and Chemotherapy. Churchill Livingstone, Edinburgh, 1981, p. 464–478.Google Scholar
  11. 11.
    Davies, B. I., Maesen, F. P. V., Brouwers, J. Cefoperazone in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1982, 9: 149–155.PubMedCrossRefGoogle Scholar
  12. 12.
    Davies, B., Maesen, F. Serum and sputum antibiotic levels after ampicillin, amoxycillin and bacampicillin in chronic bronchitis patients. Infection 1979, 7, Supplement 5: 465–468.CrossRefGoogle Scholar
  13. 13.
    Wijnands, W. J. A., Van Herwaarden, C. L. A., Vree, T. B. Enoxacin raises plasma theophylline concentrations. Lancet 1984, ii: 108.CrossRefGoogle Scholar
  14. 14.
    Maesen, F. P. V., Teengs, J. P., Baur, C., Davies, B. I. Quinolones and raised plasma concentrations of theophylline. Lancet 1984, ii: 530.CrossRefGoogle Scholar
  15. 15.
    Davies, B. I., Maesen, F. P. V., Brombacher, P. J., Sjövall, J. Twice daily dosage of bacampicillin in chronic bronchitis: a double blind study. Scandinavian Journal of Respiratory Diseases 1978, 59: 249–256.PubMedGoogle Scholar
  16. 16.
    Davies, B. I., Maesen, F. P. V. The diagnosis and treatment of respiratory infections. In: Brumfitt, W., Hamilton-Miller, J. M. T. (ed.): A clinical approach to progress in infectious diseases. Oxford University Press, Oxford, 1983, p. 132–158.Google Scholar
  17. 17.
    Wise, R. The activity of quinolones against respiratory tract pathogens. In: Shah, P. M. (ed.): Quinolones bulletin. M. I. Publications, Frankfurt, 1985, p. 1–2.Google Scholar
  18. 18.
    Reeves, D. S., Bywater, M. J., Holt, H. A., White, L. O. In vitro studies with ciprofloxacin, a new 4-quinolone compound. Journal of Antimicrobial Chemotherapy 1984, 13: 333–346.PubMedCrossRefGoogle Scholar
  19. 19.
    Barry, A. L., Jones, R. N. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin and oxolinic acid after in vitro selection of resistant populations. Antimicrobial Agents and Chemotherapy 1984, 25: 775–777.PubMedCrossRefGoogle Scholar
  20. 20.
    Crook, S. M., Selkon, J. B., McLardy-Smith, P. D. Clinical resistance to long-term oral ciprofloxacin. Lancet 1985, i: 1275.CrossRefGoogle Scholar
  21. 21.
    Chapman, S. T., Speller, D. C. E., Reeves, D. S. Resistance to ciprofloxacin. Lancet 1985, ii: 39.CrossRefGoogle Scholar
  22. 22.
    Editorial The quinolones. Lancet 1984, i: 24–25.Google Scholar

Copyright information

© Springer Fachmedien Wiesbaden 1986

Authors and Affiliations

  • B. I. Davies
    • 1
  • F. P. V. Maesen
    • 2
  • C. Baur
    • 2
  1. 1.Department of Medical MicrobiologyDe Wever ZiekenhuisHeerlenThe Netherlands
  2. 2.Department of Respiratory DiseasesDe Wever ZiekenhuisHeerlenThe Netherlands

Personalised recommendations